STADA Arzneimittel Aktiengesellschaft
STADA Arzneimittel Aktiengesellschaft, commonly known as STADA, is a prominent player in the global pharmaceutical industry, headquartered in Bad Vilbel, Germany. Founded in 1895, the company has established a strong presence in Europe and beyond, focusing on the development, manufacturing, and marketing of generic and over-the-counter (OTC) products. STADA's core offerings include a diverse range of pharmaceuticals, particularly in the fields of pain management, dermatology, and respiratory health. The company is recognised for its commitment to quality and innovation, which has positioned it as a trusted provider in the healthcare sector. With a robust portfolio and a strategic focus on expanding its market reach, STADA continues to achieve significant milestones, reinforcing its status as a leader in the pharmaceutical landscape.
DitchCarbon Score
How does STADA Arzneimittel Aktiengesellschaft's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
STADA Arzneimittel Aktiengesellschaft's score of 51 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
STADA Arzneimittel Aktiengesellschaft's reported carbon emissions
In 2024, STADA Arzneimittel Aktiengesellschaft reported total carbon emissions of approximately 40923100 kg CO2e for Scope 1, 29853600 kg CO2e for Scope 2, and a significant 680611000 kg CO2e for Scope 3 emissions. This reflects a total of about 70776700 kg CO2e for combined Scope 1 and 2 emissions. The previous year, 2023, saw similar figures with Scope 1 emissions at approximately 40104500 kg CO2e, Scope 2 at 41723200 kg CO2e, and Scope 3 at 672806000 kg CO2e, leading to a combined total of about 81827700 kg CO2e for Scope 1 and 2. STADA has set ambitious climate commitments, aiming for a 42% reduction in its Scope 1 and 2 emissions by 2030, using 2020 as the baseline year. This target aligns with the 1.5°C global warming target and reflects the company's commitment to sustainability. Additionally, STADA has achieved a 33.7% reduction in its Scope 1 emissions over the past four years, demonstrating progress towards its goals. The emissions data is cascaded from STADA Arzneimittel Aktiengesellschaft, which is committed to transparency and accountability in its climate initiatives. The company is actively working to reduce its carbon footprint in the pharmaceutical sector, contributing to broader industry efforts to combat climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 31,639,700 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,032,800 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
STADA Arzneimittel Aktiengesellschaft is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
